Further validation of these new findings and frequently mutated genes (e.g., UNC13D, CX3CR1) is helpful for determining the pathogenesis of T cell dysfunction and developing novel therapeutic strategies for CAR modification in r/r DLBCL. This evidence concerns the gene CX3CR1 and diffuse large B-cell lymphoma.